



Product Specification Sheet

Product Name: BAF312

Catalog Number: C2233

Technical information:

Chemical Formula: $C_{29}H_{35}F_3N_2O_3$

CAS #: 1230487-00-9

Molecular Weight: 516.6

Purity: > 98%


Appearance: White solid

Solubility: Soluble in DMSO up to 200mM

Chemical Name: (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid

Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



- Handling:**
- To make 10 mM stock solution, add 0.194mL of DMSO for each mg of BAF312.
 - For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

Biological Activity: BAF312 (Siponimod) is a potent sphingosine-1 receptor (S1P-R) modulator selectively targeting S1P1 and S1P5 receptors [1]. BAF312 reduces inflammation by sequestering lymphocytes in lymphoid tissues [2]. BAF312 also binds its receptors on neurons, astrocytes and oligodendrocytes and present neuroprotective effects [3]. Siponimod showed neuroprotective effects in the CNS of encephalomyelitis mice and organotypic cultures. is currently under investigation in a clinical trial in secondary progressive multiple sclerosis patients [4].

- Reference:**
1. Pan S, et al. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013; 4(3): 333–337. Pubmed ID: 24900670
 2. Hundede P, et al. The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis. Neural Regen Res 2019; 14:1950-60 Pubmed ID: 31290453
 3. Gentile A, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016; 13(1): 207. Pubmed ID: 27566665
 4. Kappos L, et al. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis
Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. JAMA Neurol 2016;73(9):1089-98. Pubmed ID: 27380540

To reorder: <http://www.cellagentech.com/BAF312/>

For Technical Support: technical@cellagentech.com

Chemicals are sold for research use only, not for clinical or diagnostic use.